Akèy › Maladi fwa
Etid klinik pou Maladi fwa ap rekrite nan Etazini
32 etid pou Maladi fwa ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX10 etid
- Chicago, IL9 etid
- Washington, DC8 etid
- Los Angeles, CA7 etid
- Atlanta, GA7 etid
- San Antonio, TX6 etid
- New York City, NY6 etid
- Richmond, VA6 etid
- Philadelphia, PA6 etid
- Dallas, TX5 etid
- Ann Arbor, MI5 etid
- Durham, NC5 etid
- Detroit, MI4 etid
- Cleveland, OH4 etid
- San Diego, CA4 etid
- Pittsburgh, PA4 etid
- Orlando, FL4 etid
- Chandler, AZ4 etid
- Austin, TX4 etid
- St. Louis, MO4 etid
- Little Rock, AR4 etid
- Miami, FL4 etid
- Aurora, CO4 etid
- Baltimore, MD4 etid
- Salt Lake City, UT4 etid
- Nashville, TN4 etid
- Cincinnati, OH4 etid
- Rochester, MN3 etid
- Jacksonville, FL3 etid
- South Bend, IN3 etid
- Monroe, LA3 etid
- Dayton, OH3 etid
- Huntington Beach, CA3 etid
- Parma, OH3 etid
- Fort Worth, TX3 etid
- Fayetteville, NC3 etid
- Tucson, AZ3 etid
- Akron, OH3 etid
- Brownsville, TX3 etid
- Ocala, FL3 etid
Pa eta
- Arizona5 etid
- Arkansas4 etid
- Colorado6 etid
- Florid8 etid
- Georgia8 etid
- Illinois9 etid
- Indiana6 etid
- Kalifòni12 etid
- Kansas3 etid
- Kentucky3 etid
- Lwizyàn3 etid
- Maryland9 etid
- Massachusetts5 etid
- Michigan8 etid
- Minnesota3 etid
- Missouri5 etid
- Nevada3 etid
- New Jersey3 etid
- New York7 etid
- North Carolina6 etid
- Ohio7 etid
- Pennsylvania8 etid
- South Carolina3 etid
- Tennessee4 etid
- Texas14 etid
- Utah6 etid
- Virginia6 etid
- Washington3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 24, 2026 · NCT07654283Evaluation of Patients With Liver Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 24, 2026 · NCT00001971Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT04685200Natural History of Noncirrhotic Portal Hypertension
Ap rekriteEtid obsèvasyon
Laj 12 a 100 · Tout sèks · Mizajou Sep 22, 2026 · NCT02417740Observational Pharmaco-Epidemiology Research & Analysis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 0 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT03813862Study of Resmetirom in Children and Adolescents With MASH
Ap rekriteFaz 2
Laj 6 a 17 · Tout sèks · Mizajou Sep 11, 2026 · NCT07763015A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT07288138A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 3, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06318169Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Ap rekriteEtid obsèvasyon
7 Months – 15 Months · Tout sèks · Mizajou Aug 31, 2026 · NCT06805695Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07010315Primary Sclerosing Cholangitis in Children
Ap rekriteEtid obsèvasyon
Laj 2 a 25 · Tout sèks · Mizajou Jul 14, 2026 · NCT04181138Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Jun 25, 2026 · NCT06068491Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 25, 2026 · NCT06138821A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT06600321A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
Ap rekriteFaz 1
Laj 18 a 80 · Tout sèks · Mizajou Jun 16, 2026 · NCT07559474Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT03193151Metabolic Responses to Bariatric Surgery
Ap rekriteEtid obsèvasyon
Laj 18 a 55 · Tout sèks · Mizajou May 18, 2026 · NCT02024542Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT06464952DILIN - Prospective Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 ak plis · Tout sèks · Mizajou Apr 8, 2026 · NCT00345930Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Feb 3, 2026 · NCT06269510MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 14, 2026 · NCT05264051A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 15, 2025 · NCT06619561The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 4, 2025 · NCT06871111A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 24, 2025 · NCT05733832Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.